Jounce Therapeutics Highlights Exciting Research at SITC and ESMO-IO Conferences
Exciting Advancements in Cancer Immunotherapy
Cambridge, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) – Jounce Therapeutics, Inc. (NASDAQ: JNCE) is set to showcase groundbreaking research at two prestigious conferences, the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting and the European Society for Medical Oncology’s Immuno-Oncology Congress (ESMO-IO).
Two preclinical posters will be presented at SITC 2022, highlighting the promising JTX-1484 program and the exciting developments within the LILRB family. These presentations will shed light on the innovative approaches being taken by Jounce Therapeutics in the fight against cancer.
Additionally, two clinical posters will feature data from the SELECT and INNATE trials at ESMO-IO. These posters will showcase the real-world impact of Jounce Therapeutics’ research, providing valuable insights into the efficacy of their therapies.
Jounce Therapeutics is at the forefront of cancer immunotherapy, leveraging cutting-edge technologies to develop novel treatments that have the potential to transform patient care. By presenting their research at these esteemed conferences, Jounce Therapeutics is demonstrating their commitment to advancing the field of oncology.
How Will This Affect Me?
As a patient, the research presented by Jounce Therapeutics at SITC and ESMO-IO could have a significant impact on your treatment options. Their groundbreaking discoveries may lead to the development of more effective and targeted therapies, offering new hope for those affected by cancer.
How Will This Affect the World?
The research presented by Jounce Therapeutics has the potential to shape the future of cancer treatment on a global scale. By advancing our understanding of cancer immunotherapy, Jounce Therapeutics is paving the way for innovative therapies that could benefit patients around the world.
Conclusion
Jounce Therapeutics’ participation in the SITC and ESMO-IO conferences signifies a significant milestone in the field of cancer research. Their dedication to advancing the science of immunotherapy is commendable, and the impact of their discoveries is poised to be felt by patients and healthcare providers worldwide.
